Thu. 7 Mar 2024, 7:03am ET
Benzinga
Earnings, News
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.49) by 32.65 percent. This is a 71.55 percent increase over losses of $(1.16) per share from the same period last year. The company reported quarterly sales of $14.03 million which beat the analyst consensus estimate of $8.90 million by 57.62 percent. This is a 33.18 percent increase over sales of $10.53 million the same period last year.